Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.

It has become the first company to receive the market authorisation for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The authorisation covers the 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).

Canada is recognised as the world’s second-largest market for Semaglutide, Dr. Reddy’s said, citing IQVIA MAT Q3 2025 numbers.